Advances and Challenges in Managing Hepatitis D Virus: Evolving Strategies

Overview

Journal Curr Hepatol Rep

Publisher Springer

Specialty Gastroenterology

Date 2024 Mar 27

PMID 38533303

Authors

Harish Gopalakrishna

Maria Mironova

Harel Dahari

Christopher Koh

Theo Heller

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Hepatitis D Virus (HDV), although a small defective virus, poses a substantial public health challenge due to lack of awareness, underrecognized prevalence, and limited treatment options. Universal HDV screening within hepatitis B virus (HBV) cohorts is essential to address this issue. Despite its aggressive nature, effective HDV therapies have remained elusive for over four decades.

Recent Findings: Advances in understanding HDV's biology and clinical behavior offer potential therapeutic breakthroughs, fostering optimism. As insights grow, effective and targeted therapies are being developed to improve HDV management.

Summary: This review delves into HDV's intricate structure and biology, highlighting formidable hurdles in antiviral development. It emphasizes the importance of widespread screening, exploring noninvasive diagnostics, and examining current and emerging innovative therapeutic strategies. Moreover, the review explores models for monitoring treatment response. In essence, this review simplifies the complexities of effectively combating HDV.

Citing Articles

Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study.

Rinaldi L, Vigano M, Ciancio A, Caturano A, Messina V, Niro G Viruses. 2025; 17(2).

PMID: 40007006 PMC: 11860205. DOI: 10.3390/v17020251.

Hepatitis C Virus as a Possible Helper Virus in Human Hepatitis Delta Virus Infection.

Crobu M, Ravanini P, Impaloni C, Martello C, Bargiacchi O, Di Domenico C Viruses. 2024; 16(6).

PMID: 38932284 PMC: 11209499. DOI: 10.3390/v16060992.

References

Le Gal F, Dziri S, Gerber A, Alloui C, Ben Abdesselam Z, Roulot D . Performance Characteristics of a New Consensus Commercial Kit for Hepatitis D Virus RNA Viral Load Quantification. J Clin Microbiol. 2016; 55(2):431-441. PMC: 5277512. DOI: 10.1128/JCM.02027-16. View

Hercun J, Kim G, Da B, Rotman Y, Kleiner D, Chang R . Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy. Aliment Pharmacol Ther. 2021; 54(2):176-182. PMC: 9969742. DOI: 10.1111/apt.16408. View

Da B, Rahman F, Lai W, Kleiner D, Heller T, Koh C . Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened?. Am J Gastroenterol. 2020; 116(1):206-209. PMC: 9205618. DOI: 10.14309/ajg.0000000000000954. View

Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W . Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis. 2019; 221(10):1677-1687. PMC: 7184909. DOI: 10.1093/infdis/jiz633. View

Gudima S, Chang J, Moraleda G, Azvolinsky A, Taylor J . Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA. J Virol. 2002; 76(8):3709-19. PMC: 136113. DOI: 10.1128/jvi.76.8.3709-3719.2002. View

Romeo R, Foglieni B, Casazza G, Spreafico M, Colombo M, Prati D . High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS One. 2014; 9(3):e92062. PMC: 3962389. DOI: 10.1371/journal.pone.0092062. View

Razavi H, Buti M, Terrault N, Zeuzem S, Yurdaydin C, Tanaka J . Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries. J Hepatol. 2023; 79(2):576-580. DOI: 10.1016/j.jhep.2023.02.041. View

Zhang Z, Urban S . New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies. J Hepatol. 2020; 74(3):686-699. DOI: 10.1016/j.jhep.2020.11.032. View

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

10.

OMalley B, Lazinski D . Roles of carboxyl-terminal and farnesylated residues in the functions of the large hepatitis delta antigen. J Virol. 2004; 79(2):1142-53. PMC: 538544. DOI: 10.1128/JVI.79.2.1142-1153.2005. View

11.

Greco-Stewart V, Miron P, Abrahem A, Pelchat M . The human RNA polymerase II interacts with the terminal stem-loop regions of the hepatitis delta virus RNA genome. Virology. 2006; 357(1):68-78. DOI: 10.1016/j.virol.2006.08.010. View

12.

Bremer B, Anastasiou O, Ciesek S, Wedemeyer H . Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation. Antivir Ther. 2018; 24(2):117-123. DOI: 10.3851/IMP3281. View

13.

Yang A, Yardeni D, Hercun J, Kleiner D, Ling A, Marko J . Shear wave elastography: How well does it perform in chronic hepatitis D virus infection?. J Viral Hepat. 2022; 29(12):1127-1133. PMC: 10673679. DOI: 10.1111/jvh.13745. View

14.

Kamal H, Westman G, Falconer K, Duberg A, Weiland O, Haverinen S . Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. Hepatology. 2020; 72(4):1177-1190. DOI: 10.1002/hep.31214. View

15.

Shekhtman L, Cotler S, Hershkovich L, Uprichard S, Bazinet M, Pantea V . Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. Sci Rep. 2020; 10(1):7837. PMC: 7217939. DOI: 10.1038/s41598-020-64122-0. View

16.

Guedj J, Rotman Y, Cotler S, Koh C, Schmid P, Albrecht J . Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology. 2014; 60(6):1902-10. PMC: 4245461. DOI: 10.1002/hep.27357. View

17.

Yurdaydin C, Keskin O, Kalkan C, Karakaya F, Caliskan A, Kabacam G . Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease. J Infect Dis. 2018; 217(8):1184-1192. DOI: 10.1093/infdis/jix656. View

18.

Manini M, Whitehouse G, Bruce M, Passerini M, Lim T, Carey I . Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. Dig Liver Dis. 2018; 50(9):944-953. DOI: 10.1016/j.dld.2018.03.032. View

19.

Takyar V, Surana P, Kleiner D, Wilkins K, Hoofnagle J, Liang T . Noninvasive markers for staging fibrosis in chronic delta hepatitis. Aliment Pharmacol Ther. 2016; 45(1):127-138. PMC: 5135658. DOI: 10.1111/apt.13834. View

20.

Giersch K, Bhadra O, Volz T, Allweiss L, Riecken K, Fehse B . Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo. Gut. 2017; 68(1):150-157. DOI: 10.1136/gutjnl-2017-314713. View